Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02SNQ
|
|||
| Drug Name |
Pyrazole derivative 8
|
|||
| Synonyms |
PMID26161824-Compound-18
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Company |
Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H18Cl2F4N4O2
|
|||
| Canonical SMILES |
C1CN(CCC1(F)F)NC(=O)C2=NN(C(=C2OC(F)F)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl
|
|||
| InChI |
1S/C22H18Cl2F4N4O2/c23-14-7-5-13(6-8-14)18-19(34-21(25)26)17(29-32(18)16-4-2-1-3-15(16)24)20(33)30-31-11-9-22(27,28)10-12-31/h1-8,21H,9-12H2,(H,30,33)
|
|||
| InChIKey |
UTHOXBJQLSAVTJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.